This unique dual formulation provides the potential benefit for smooth transition from short-term intravenous to long-term oral antiplatelet therapy. It has a plasma half-life of approximately 12 ...

In updated American recommendations for the management of acute coronary syndrome (ACS), bleeding reduction strategies on antiplatelet therapy are embraced, as are non-statin lipid-lowering therapies ...

No writing assistance was utilized in the production of this manuscript. The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of ...